A Next Generation Cancer Treatment - Killing Cancer Tumors From The Inside Out
VIVOS INC Precision Radionuclide Therapy™ (PRnT™)
Vivos Inc. is a medical device company with its patented Precision Radionuclide Therapy™.
Vivos Inc.
The Next Generation Cancer Treatment
RadioGel® for Human Cancer
Precision Radionuclide Therapy™ (PRnT™)
Precision Radionuclide Therapy™ (PRnT™)
RadioGel®, not currently approved for human use, is our division dedicated to treating cancer in humans using our patented Precision Radionuclide Therapy™ (PRnT™). RadioGel® is a hydrogel liquid containing tiny yttrium-90 phosphate micro-particles that may be administered directly into a tumor. We are currently in the final stages of completing all FDA requirements for IDE submission.
Precision Radionuclide Therapy™ (PRnT™)
Precision Radionuclide Therapy™ (PRnT™)
Precision Radionuclide Therapy™ (PRnT™)
Our patented Precision Radionuclide Therapy™ (PRnT™) is the future of radionuclide cancer treatment – the insertion of our radionuclide device directly into the tumor tissue.
IsoPet® for Animal Cancer
Precision Radionuclide Therapy™ (PRnT™)
IsoPet® for Animal Cancer
IsoPet® is our division dedicated to treating cancers in animals using our patented Precision Radionuclide Therapy™ (PRnT™). Our innovative approach in the treatment of cancerous tumors focuses on delivering targeted radiation directly to cancerous tumors in a single treatment while minimizing damage to surrounding healthy tissues.
Research Papers
Research Papers
IsoPet® for Animal Cancer
Direct Interstitial Treatment of Solid Tumors Using an Injectable Yttrium-90-Polymer Composite
Published online 2020 Feb 5
Darrell R. Fisher,1 Janean Fidel,2 and Charles A. Maitz3
IDE Submission
Research Papers
IDE Submission
IDE submission marks our first filing with the FDA following the grant of the FDA Breakthrough Device Designation for the RadioGel® Precision Radionuclide Therapy.
Press Releases
Research Papers
IDE Submission
Press Releases - Vivos Inc.
GlobeNewsWire has a list of all press releases and is the only place for the most accurate and up to date information on our revolutionary cancer treatment - Precision Radionuclide Therapy™ (PRnT™)
Investor Relations
Vivos Inc. Articles
Investor Relations
We are trading under the OTCQB: RDGL and value our very loyal shareholders and followers and strive to have the most accurate and up to date information on our stock information.
SEC Filings
Vivos Inc. Articles
Investor Relations
We are pleased to provide the following the most up to date SEC filings through www.sec.gov
Vivos Inc. Articles
Vivos Inc. Articles
Vivos Inc. Articles
We are pleased to provide you with our Quarterly Reports